Modified (m) Folfox7/bevacizumab (B) or modified (m) Xelox/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal cancer (MCRC): Results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR)

被引：0
|
作者：
Tournigand, C.
Lledo, G.
Delord, J.
Andre, T.
Maindrault-Goebel, F.
Louvet, C.
Scheithauer, W.
de Gramont, A.
机构：
[1] Hop St Antoine, Paris, France
[2] Clin St Jean, Lyon, France
[3] Ctr Claudius Regaud, Toulouse, France
[4] Hop Tenon, Paris, France
[5] Univ Vienna, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4097
引用
收藏
页数：1
相关论文
共 50 条
  • [31] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [32] Updated phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V
    ANNALS OF ONCOLOGY, 2009, 20 : 76 - 76
  • [34] Capecitabine (X), irinotecan (I) and bevacizumab (A) as first-line therapy for patients (PTS) with metastatic colorectal cancer (MCRC): Preliminary phase II study results
    Semir, Beslija
    Maja, Banjin
    Nadja, Paraganlija
    Timur, Ceric
    Anes, Pasic
    Berisa, Salkic
    Anes, Sosevic
    Nermina, Obralic
    ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [35] Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
    Lenz, Heinz-Josef
    Parikh, Aparna
    Spigel, David R.
    Cohn, Allen L.
    Yoshino, Takayuki
    Kochenderfer, Mark
    Elez, Elena
    Shao, Spencer H.
    Deming, Dustin
    Holdridge, Regan
    Larson, Timothy
    Chen, Eric
    Mahipal, Amit
    Ucar, Antonio
    Cullen, Dana
    Baskin-Bey, Edwina
    Kang, Tong
    Hammell, Amy B.
    Yao, Jin
    Tabernero, Josep
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
  • [36] First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs. FOLFOX4+bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC)
    Cassidy, Jim
    Clarke, Stephen
    Rubio, Eduardo Diaz
    Scheithauer, Werner
    Figer, Arie
    Wong, Ralph
    Koski, Sheryl
    Lichinitser, Mikhail
    Yang, Tsai-Shen
    Saltz, Leonard
    ANNALS OF ONCOLOGY, 2006, 17
  • [37] Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
    Mooi, Jennifer
    Chionh, Fiona
    Savas, Peter
    Duarte, Jessica Da Gama
    Chong, Geoffrey
    Brown, Stephen
    Wong, Rachel
    Price, Timothy J.
    Wann, Alysson
    Skrinos, Effie
    Mariadason, John M.
    Tebbutt, Niall C.
    CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2159 - 2167
  • [38] Phase I/II study of capecitabine(C)/oxaliplatin(O)/ irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Ou, K.
    Liu, X.
    Ma, X.
    Gao, L.
    Wang, Q.
    Yang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1514 - S1514
  • [39] Preliminary phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] CRAFT Trial-Result From Multicenter Phase II Study of Modified FOLFOX7 (Combination Chemotherapy of Infusional 5-FU/I-Leucovorin and Intermittent Oxaliplatin) With Bevacizumab in the First-line Therapy of Colorectal Cancer
    Ishibashi, K.
    Koda, K.
    Oshiro, M.
    Matsuoka, H.
    Baba, H.
    Ishida, H.
    Katoh, R.
    Maeda, K.
    Hamada, C.
    Sakamoto, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S421 - S421
12345